Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
|
|
- Prudence Briggs
- 5 years ago
- Views:
Transcription
1 Adv Ther (2013) 30(3): DOI /s REVIEW Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Maria I. Vazquez-Roque Ernest P. Bouras To view enhanced content go to Received: November 7, 2012 / Published online: February 20, 2013 Springer Healthcare 2013 ABSTRACT Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received M. I. Vazquez-Roque E. P. Bouras (*) Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA bouras.ernest@mayo.edu Enhanced content for Advances in Therapy articles is available on the journal web site: approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C. Keywords: Constipation; Gastroenterology; Guanylate cyclase C; Guanylin; Irritable bowel syndrome; Linaclotide; Uroguanylin BACKGROUND Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. The overall prevalence of CC in the general population is approximately 20% [1]. CC is defined by infrequent bowel movements (less than three bowel movements per week) with associated straining or the sense of incomplete emptying of the bowel. IBS-C is defined by constipation with recurrent abdominal pain that is generally relieved by defecation. Elderly patients, irrespective of gender, have a higher incidence of CC of approximately 20%. Females younger than 50 years of age have a greater incidence compared to men, 18.3% and 9.2% respectively [2, 3]. Overall, female gender, black race, fewer years of education, decreased physical activity, and depression
2 204 Adv Ther (2013) 30(3): are independent risk factors for CC [4]. CC has a significant economic burden in the US. Studies have estimated that CC accounts for 5.7 million outpatient doctor visits and 100,000 hospitalizations annually [5, 6]. Patients with CC also have a significantly negative health-related quality of life (HRQOL), significantly decreased work productivity, and increased psychological comorbidities [7 9]. The worldwide prevalence of IBS is approximately 10 15% [10]. IBS is more likely to develop in women compared to men, and it is more likely diagnosed in patients younger than 50 years of age [11]. Additionally, IBS has a significant negative impact on the HRQOL of these patients leading to significant psychological and psychiatric comorbidities [11]. Treatments for CC in the current US market include nonprescription and prescription medications. Nonprescription medications include stool softeners, fiber supplements, osmotic and stimulant laxatives, such as polyethylene glycol and milk of magnesia and bisacodyl, respectively. Lubiprostone is the only prescription medication approved in the US for CC and IBS-C. Tegaserod was a previously approved medication for IBS-C that, although effective, was withdrawn from the US market due to reported adverse effects. Overall, these treatments have variable benefit and efficacy, and there is still great demand for more efficacious and safer treatments for these chronic conditions. Newer therapies for CC and IBS-C have been developed with novel mechanism of actions. Other agents that are either in clinical trials or approved in Europe to treat CC or IBS-C include the uroguanylin (UG) analog plecanatide [12]; prokinetics such as prucalopride [13], velusetrag [12], and naronapride [12]; and the ileal bile acid transporter inhibitor, elobixibat, which increases bile acid concentration in the colon leading to accelerated colonic transit [14]. LINACLOTIDE Linaclotide is a guanylin (GN) and UG analog that activates the guanylate cyclase-c (GC-C) receptor. GN and UG are endogenous peptides of the GN peptide family that are produced by the enteroendocrine cells and activate the GC-C receptor, increasing intestinal fluid secretion [15]. The GC-C receptor is expressed in enterocytes from the small intestine to the distal colon and it is the transmembrane receptor for the heat stable enterotoxin (STa) responsible for acute secretory diarrhea [15]. Activation of the GC-C receptor on the lumen of intestinal epithelial cells stimulates the intrinsic GC-C activity that leads to increases in intracellular cyclic guanosine monophosphate (cgmp), which in turn leads to phosphorylation of a cgmp-dependent protein kinase II and phosphorylation of the cystic fibrosis transmembrane conduction regulator (CFTR). Activation of the CFTR channel results in chloride and fluid secretion into the lumen that leads to increased colonic transit [16]. Chemistry Linaclotide is a 14-amino acid peptide with three disulfide bonds [3, 17] with a structure analogous to the endogenous peptides GN and UG. Linaclotide is stabilized by three intramolecular disulfide bonds, similar to the two disulfide bonds in GN and UG [16]. However, the UG sequence has two N-terminal aspartate residues that are not in the amino acid sequence of linaclotide [16]. Mechanism of Action Linaclotide binds to the GC-C receptor and stimulates intestinal secretion by increasing the production of cgmp. Increased intracellular cgmp leads to phosphorylation
3 Adv Ther (2013) 30(3): Lumen Linaclotide CI HCO 3 Na + H 2 O GC-C receptor and that this effect is abolished in GC-C null mice. GC-C CFTR Pharmacology Serosa GTP cgmp Afferent pain fibers Fig. 1 Mechanism of action of linaclotide PKGII of a cgmp-dependent protein kinase II and phosphorylation of the CFTR, which results in chloride anion and fluid secretion into the intestinal lumen (Fig. 1). The GC-C receptor is the key receptor for the STa. These enterotoxins are produced by organisms, such as Escherichia coli, and activate the GC-C receptor causing an acute secretory diarrhea. The specific function of this receptor has been confirmed in GC-C null mice, which fail to elicit the STa stimulation of fluid accumulation within the intestines, evidence of the function of this receptor in intestinal fluid secretion [18]. In vitro studies using human carcinoma T84 cells have demonstrated that the binding of linaclotide occurs in the luminal side of the intestine [19]. The selective binding of linaclotide to the GC-C receptor was studied with a competitive radioligand-binding assay using a radiolabeled heat-stable enterotoxin [ 125 I]-STa in GC-C wild-type and null mice. In wild-type mice, linaclotide inhibited binding of [ 125 I]-STa in a concentration-dependent manner. However, in GC-C null mice a low level of residual binding of [ 125 I]-STa to intestinal mucosa was demonstrated, an effect that was inhibited by linaclotide [16]. This is evidence that linaclotide binds to the Human and animal studies have been published demonstrating the pharmacodynamic and pharmacokinetic properties of linaclotide. In vitro studies have shown that linaclotide is stable in an acidic ph and it resists degradation from gastric hydrolases. Linaclotide did not degrade after 3 hours in a gastric ph of 1, and it resisted hydrolysis from pepsin, suggesting that it would be an adequate medication to administer orally [20]. Six hours after intravenous and oral administration of linaclotide minimal absorption was documented with an oral bioavailability of 0.1% [20, 21]. The limited oral bioavailability of linaclotide causes no serious systemic side effects. MM , the active metabolite of linaclotide, has comparable pharmacokinetics and oral bioavailability to the parent compound. Therefore, it is unlikely that the active metabolite of linaclotide will have clinically significant adverse effects [22]. Pharmacodynamics The pharmacodynamic effects of linaclotide in intestinal motility and secretion have been validated in animal studies [20]. In female rats, acceleration in GI motility was demonstrated in gavage studies. Charcoal traveled a greater distanced in a dose-dependent manner with linaclotide. Secretion, determined by the weight and length of excised ligated small intestine (SI) loops from mice, was increased in the lumen of wild-type mice exposed to linaclotide compared to vehicle-treated animals (P < 0.001). There were no differences in secretion in SI loops from GC-C null mice exposed to linaclotide compared to
4 206 Adv Ther (2013) 30(3): the vehicle. Linaclotide increased the secretion of cgmp in wild-type mice but this effect was abolished in GC-C null mice. This confirms the mechanism of action of linaclotide on the GC-C receptor, resulting in increasing fluid secretion. Animal studies have suggested that linaclotide may have a hyperalgesic effect [21, 23]. Using the trinitrobenzene sulfonic acid (TNBS) colitis rodent model, Eutamene and colleagues evaluated the antinociceptive effects of linaclotide [23]. They used colorectal distention (CRD) as a visceromotor response of pain in mice [23]. They demonstrated a significant reduction in the observed TNBS-induced abdominal wall contractions in response to CRD (P < 0.05) with escalating doses of orally administered linaclotide (0.01, 0.03, 0.3 µg/kg) [23]. A similar effect was not observed with the higher dose of linaclotide arguing against a dose-dependent effect and the strength of its visceral analgesic effects. Using GC-C wild-type and GC-C null mice, linaclotide reversed the hypersensitivity response induced by TNBS in the GC-C wild-type mice, but not in the GC-C null mice. These data suggest that the GC-C receptor may mediate the antinociceptive effects of linaclotide. An acute restraint stress-induced visceral hyperalgesia (PRS) model was also used to evaluate the antinociceptive effects of linaclotide. Linaclotide at doses of 0.3, 3.0, and 30.0 µg/kg were administered; however, a significant effect in reducing hyperalgesia to CRD was seen in the 3.0 µg/kg dose (P < 0.05). In another model of stress, acute water avoidance (WAS) delayed stress-induced visceral hyperalgesia in male Wistar rats [23]; visceral hyperalgesia was determined by performing CRD as a painful stimulus to evoke EMG responses from electrodes placed in the abdominal wall. The EMG response after CRD was completely abolished after oral linaclotide at doses 0.3 and 3.0 µg/kg. A recent animal study, using C57/BL6 mice, which were mechanically hypersensitive 28 days after TNBS exposure, sought to elucidate the mechanism of action of pain relief with linaclotide [24]. Linaclotide reduced nociceptor mechanosensitivity in viscerally sensitive mice at 100, 300, and 1,000 nm doses, in a dose-dependent response with the greatest effect seen in the 1,000 nm dose. These effects in nociception are similar to those seen in exogenously applied cgmp; however, it seems the GC-C agonists are more potent. Overall, the analgesic effects of linaclotide are seen in colonic sensitivity animal models and recent data show a dose-dependent effect in mechanosensitivity. However, additional studies are necessary to elucidate the analgesic mechanisms by which linaclotide reduces pain in humans. METHODS A search of the published literature using the PubMed database was performed. Search dates were from 2005 until November Separate searches using the key terms linaclotide, MD-1100, irritable bowel syndrome, and chronic constipation (English language) were combined (using the AND operator) with adults, followed by additional search terms as text terms. Results were limited to human trials, animal studies, English language, adults, and full manuscripts. For this review paper, all available data were reviewed and no studies were excluded. Press releases from Ironwood Pharmaceuticals were also reviewed. Clinical Trials The clinical efficacy of linaclotide has been demonstrated in phase 1, 2, and 3 trials of patients with CC and IBS-C. Linaclotide
5 Adv Ther (2013) 30(3): from 30 to 300 µg per day was given to 30 healthy volunteers in a phase 1 clinical trial and was the first study to confirm that it was safe and had no significant adverse events [17, 25]. A trial using a single oral ascending dose of linaclotide in 30 healthy participants demonstrated looser stool consistency using the Bristol stool form scale [26]. In a doseranging study of 48 healthy volunteers, linaclotide at 30, 100, 300, or 1,000 µg dose or placebo was given orally once daily for 7 days. There was a dose response and significant difference in stool consistency and in ease of passage of stool with the 1,000 µg dose. [27]. Pharmacodynamic effects of linaclotide were evaluated in a double-blind, placebo-controlled, randomized, multiple repeat-dose study of linaclotide 100 µg, 1,000 µg, and placebo orally once daily for 5 days in 36 females with IBS-C [28]. In this trial, linaclotide at a dose of 1,000 µg accelerated ascending colonic transit and colonic transit at 48 hours. Linaclotide also improved bowel function and was well tolerated with no adverse or safety concerns. A randomized, double-blind, placebocontrolled efficacy trial of linaclotide was conducted to evaluate its safety in 42 patients with CC [29]. Patients were randomized to receive 100, 300, or 1,000 µg of linaclotide or placebo once daily for 14 days. Rebound constipation was assessed in an 8-day posttreatment period. Efficacy parameters were daily bowel movements using weekly rates of spontaneous bowel movements (SBM), complete SBM (CSBM), stool consistency, straining, and complete evacuation. At all doses studied, linaclotide produced an increase in SBM and CSBM compared to the placebo [29]. A phase 2b clinical trial in patients with CC was performed to evaluate the primary endpoint of SBM and secondary endpoints of CSBM, stool consistency, abdominal discomfort, and bloating. This trial randomized 310 patients with CC to four doses of linaclotide or placebo once daily for 4 weeks [30]. There was a dose response for linaclotide at the studied doses of 75, 150, 300, or 600 µg with an increase mean weekly SBM compared to the placebo [30]. There was an overall improvement in the other secondary endpoints and global measures of constipation and HRQOL in patients on linaclotide compared to the placebo. A study of IBS-C patients was conducted to evaluate the efficacy and safety of linaclotide doses of 75, 150, 300, or 600 µg or placebo for 12 weeks [31]. The primary endpoint was the difference from baseline in the number of CSBM per week. Secondary endpoints were the change from baseline in abdominal pain, bloating, and bowel function. All endpoints, primary and secondary, improved at all linaclotide doses (P 0.01 for each dose). Patients treated with linaclotide had significant improvement in abdominal pain, discomfort, bloating, and global measures of IBS symptoms. There were no significant adverse events, and the most common reported side effect was diarrhea at all doses. Table 1 summarizes the phase 3 trials that have been conducted to date of linaclotide in CC and IBS-C patients [32 34]. Two randomized, multicenter, double-blind, placebo-controlled, dual-dose trials, denoted 303 and 01, in 1,276 patients with CC were conducted [32]. Only 1,272 patients were included in the intention-totreat analysis because four patients who received at least one dose of the study medication did not report CSBM and were not included in the analysis. Trials 303 and 01 were identical with the only difference that trial 303 had a 4-week period of randomized withdrawal after the treatment period. Trial 303 included 642 patients and trial 01 included 630 patients (intent-to-treat population). The patients were randomized to
6 208 Adv Ther (2013) 30(3): Table 1 Phase 3 trials of linaclotide in chronic constipation and irritable bowel syndrome with constipation Author Trial n Linaclotide dose (µg/d) Duration Primary endpoints Results (% patients) Ref Chronic constipation Lembo, et al. Lembo, et al or weeks and 4-week randomized withdrawal a) 3 CSBM and increase 1 from baseline for 9 of 12 weeks or weeks a) 3 CSBM and increase 1 from baseline for 9 of 12 weeks Irritable bowel syndrome with constipation Rao, et al. Chey, et al weeks and 4-week randomized withdrawal a) Composite responder: abdominal pain and CSBM ( 30% reduction in pain and increase 1 from baseline for 6 of 12 weeks) b) 3 CSBM from baseline for 9 of 12 weeks c) Abdominal pain responder ( 30% reduction in pain at least 9 of 12 weeks) d) CSBM increase 1 from baseline for 9 of 12 weeks weeks a) Composite responder: abdominal pain and CSBM ( 30% reduction in pain and 3 CSBM and 1 from baseline for 9 of 12 weeks) b) CSBM responder ( 3 CSBM and 1 from baseline for 9 of 12 weeks) c) Abdominal pain responder ( 30% reduction in pain at least 9 of 12 weeks) d) Composite responder #2: abdominal pain and CSBM ( 30% reduction in pain and 3 CSBM and 1 from baseline for 6 of 12 weeks) CSBM complete spontaneous bowel movement a) 21.2% in 145 µg/d, 19.4% in 290 µg/d versus 3.3% placebo (P < , all groups vs. placebo) a) 16.0% in 145 µg/d (P < 0.01), 21.3% in 290 µg/d (P < ) versus 6.0% placebo a) 55% linaclotide group versus 42% placebo group (P = ) b) 37% linaclotide group versus 18% placebo group (P < ) a) Composite responder: 12.7% linaclotide versus 3.0% placebo (P < ) b) CSBM responder: 18% linaclotide group versus 5% placebo group (P <0.0001) c) Abdominal pain responder: 38.9% linaclotide group versus 19.6% placebo group (P < ) d) Composite responder #2: 33.7% linaclotide group versus 13.9% placebo group (P < ) [32] [32] [33] [34]
7 Adv Ther (2013) 30(3): linaclotide 145 or 290 µg, or placebo once daily for 12 weeks after a 14-day pretreatment period. The combined primary efficacy endpoints were three or more CSBMs per week and an increase of at least one CSBM per week from baseline for 9 or more weeks during the 12-week treatment period. In trial 303, the primary endpoint was achieved in 21.2% of patients in the 145 µg linaclotide group, 19.4% in the 290 µg group, compared to 3.3% in the placebo group [32]. In trial 01, the primary endpoint was achieved in 16.0% of patients in the 145 µg linaclotide group, 21.3% in the 290 µg group, compared to 6.0% in the placebo group [32]. All secondary endpoints (bloating, abdominal discomfort, stool consistency, straining, and constipation severity) were significantly different for the linaclotide groups compared to the placebo. There was no rebound constipation in patients that were taking linaclotide, who were randomized to receive the placebo during the 4-week randomized withdrawal period. The most common adverse events across these two phase 3 trials were diarrhea (linaclotide 14 16%, placebo 4.7%), flatulence, and abdominal pain. The overall rate of discontinuation during the 12-week trial was higher in the linaclotide group, approximately 7.5% of patients treated with linaclotide compared to 4.2% in the placebo group. This was a result of increased diarrhea in the linaclotide group compared to the placebo group. Two phase 2 trials in IBS-C patients have been conducted and recently published [33]. A multicenter, randomized, double-blind, placebo-controlled 12-week treatment trial of 800 IBS-C patients was conducted. Patients were randomized to either linaclotide 290 µg once daily or placebo followed by a 4-week randomized withdrawal period [33]. There were four primary endpoints in this study. The composite responder endpoint for abdominal pain (improvement of at least 30% from baseline on an 11-point numerical scale) and on a CSBM (an increase of at least 1 from baseline) had to be met at least 6 weeks of the 12 weeks of the treatment period to be considered a responder for this composite endpoint, this meets the US Food and Drug Administration s (FDA s) primary endpoint for IBS-C. The other three primary endpoints had to be met for at least 9 of the 12 weeks of the treatment period. These endpoints were improvement of at least 30% in abdominal pain, three or more CSBMs, and an increase of one or more CSBM from baseline. The linaclotide treatment group had a greater proportion of responders compared to the placebo, 33.6% versus 21.0%, respectively [33]. A 26-week phase 3 clinical trial was conducted assessing the efficacy and safety of linaclotide in patients with IBS-C [34]. After a 2-week pretreatment period, 804 IBS-C patients were randomized to linaclotide 290 µg once daily or placebo for the trial duration. The four primary endpoints are summarized in Table 1. Secondary endpoints included difference from baseline of abdominal pain and discomfort, bloating, percent pain-free days, CSBM weekly frequency, SBM weekly frequency, stool consistency, and straining. Linaclotide-treated patients had a greater proportion of responders for the primary composite endpoint compared to the placebo group [34]. Linaclotide-treated patients had a statistically significant difference in the other primary and secondary endpoints compared to the placebo group. Diarrhea was the most common adverse event, seen in 19.7% of patients in the linaclotide treated group and in 2.5% in the placebo group. The discontinuation rate due to diarrhea was approximately 4.5% in the linaclotide-treated patients compared to 0.2% in the placebo group. Overall, at all doses, linaclotide has been well tolerated with an adequate safety profile [26].
8 210 Adv Ther (2013) 30(3): As expected the most common reported adverse event is diarrhea in % [28 31, 34]. The diarrhea seems to be dose-dependent and it is not severe. Other reported GI adverse events that were experienced in less than 5% of the linaclotide-treated patients were abdominal pain, flatulence, and nausea, but these were not different than placebo. Linaclotide received approval by the FDA on August 30, 2012 for the treatment of chronic idiopathic constipation and IBS-C in adults. Although not fully approved by the European Commission, it has received a recommendation for approval by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of moderate to severe IBS-C. CONCLUSION Linaclotide is a drug with minimal bioavailability that induces intestinal secretion and improves stool consistency in patients with CC and IBS-C. Animal studies have suggested that linaclotide may have an effect in improving pain, and, in human studies, pain scores do improve but the exact mechanism is not well understood. Clinical trials have demonstrated the efficacy and safety of linaclotide for up to 26 weeks. Linaclotide was recently approved by the FDA in the USA. The efficacy of linaclotide in patients with other etiologies of constipation, such as pelvic floor dysfunction, needs to be further elucidated. ACKNOWLEDGMENTS Dr. Bouras is the guarantor for this article and takes responsibility for the integrity of the work as a whole. Conflict of interest. Dr. Vazquez declares she has no conflict of interest. Dr. Bouras declares he has no conflict of interest. REFERENCES 1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99: Choung RS, Locke GR, 3rd, Schleck CD, et al. Cumulative incidence of chronic constipation: a population-based study Aliment Pharmacol Ther. 2007;26: Vazquez Roque M, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol. 2011;5: Everhart JE, Go VL, Johannes RS, et al. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci. 1989;34: Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to Dig Dis Sci. 1989;34: Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. 2006;19: Bongers ME, Benninga MA, Maurice-Stam H, et al. Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood. Health Qual Life Outcomes. 2009;7: Wang JP, Duan LP, Ye HJ, et al. [Assessment of psychological status and quality of life in patients with functional constipation]. Zhonghua Nei Ke Za Zhi. 2008;47: In Chinese. 9. Sun SX, Dibonaventura M, Purayidathil FW, et al. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci. 2011;56: Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123: Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep. 2009;11: Vazquez Roque M, Camilleri M. Velusetrag. Drugs Future. 2011;36: Camilleri M, Kerstens R, Rykx A, et al. A placebocontrolled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:
9 Adv Ther (2013) 30(3): Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106: Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52: Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86: Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther. 2007;9: Schulz S, Lopez MJ, Kuhn M, et al. Disruption of the guanylyl cyclase-c gene leads to a paradoxical phenotype of viable but heat-stable enterotoxinresistant mice. J Clin Invest. 1997;100: Busby RW, Bryant AP, Cordero EA, et al. The molecular target of MD-1100 is guanylate cyclase-c (GC-C), an apical receptor on intestinal epithelial cell. Gastroenterology. 2005;128:A Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649: Bryant AP, Busby RW, Cordero EA, et al. MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology. 2005;128:A Bryant AP, Busby RW, Cordero EA, et al. The characterization of an active metabolite of MD- 1100, a therapeutic agent in development for the treatment of IBS-C and chronic constipation. Gastroenterology. 2006;130:T Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22:312-e Castro J HA, Hughes PA, Martin C, et al. Mechanism of action for linaclotide induced abdominal pain relief. Gastroenterology. 2012;142:S Brady S. Microbia succesfully completes phase IA trial of MD-1100 for IBS-C and other GI disorders Available at: com/newspdf/2005_05.17.microbia.ibs.ia.pdf. Accessed Sep Currie MG, Kurtz CB, Mahajan-Miklos S, et al. Effects of single dose administration of MD on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol. 2005;100:S Kurtz CB, Fitch DA, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology. 2006;130:A-26. Abstract Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133: Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol. 2009;104: Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138: e Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139: e Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365: Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107: Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebocontrolled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:
Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation
Review Article Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation United European Gastroenterology Journal 1(1) 7 20! Author(s) 2013 Reprints
More informationConstipation is a common chief complaint among patients
Linaclotide: A Novel Therapy for Chronic Constipation and Constipation- Predominant Irritable Bowel Syndrome Brian E. Lacy, PhD, MD, John M. Levenick, MD, and Michael D. Crowell, PhD, FACG Dr. Lacy is
More information(linzess) for irritable Bowel syndrome With Constipation and For Chronic idiopathic Constipation
DrUG FOrECAST PHarMaCoKiNEtiCs and PHarMaCoDYNaMiCs Linaclotide elicits its pharmacological effects locally in the GI tract with minilinaclotide (linzess) for irritable Bowel syndrome With Constipation
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationLinaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation
GASTROENTEROLOGY 2010;139:1877 1886 CLINICAL Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation JEFFREY M. JOHNSTON,*
More informationEfficacy of Linaclotide for Patients With Chronic Constipation
GASTROENTEROLOGY 2010;138:886 895 Efficacy of Linaclotide for Patients With Chronic Constipation ANTHONY J. LEMBO,* CAROLINE B. KURTZ, JAMES E. MACDOUGALL, B. J. LAVINS, MARK G. CURRIE, DONALD A. FITCH,
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationEvidence-based Treatment Strategies for
Evidence-based Treatment Strategies for Chronic Constipation William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria*: Chronic constipation Must include 2 of the following (>25%
More informationTwo Randomized Trials of Linaclotide for Chronic Constipation
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Two Randomized Trials of Linaclotide for Chronic Constipation Anthony J. Lembo, M.D., Harvey A. Schneier, M.D., Steven J. Shiff, M.D.,
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationEffects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
Alimentary Pharmacology and Therapeutics Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation L. Chang*, W. D. Chey, D.
More informationSlide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update
Functional Disorders: An Update Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Disclosure of Financial Relationships Anthony
More informationResponders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C
Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C The Harvard community has made this article openly available. Please share how this access
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Almirall Contact: Susan Brady Ketchum Pleon Corporate Communications Amanda Sefton 617.621.8304 +44 (0) 207.611.3653 sbrady@ironwoodpharma.com amanda.sefton@ketchumpleon.com
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationTenapanor for irritable bowel syndrome with constipation
NIHR Innovation Observatory Evidence Briefing: February 2018 Tenapanor for irritable bowel syndrome with constipation NIHRIO (HSRIC) ID: 6704 NICE ID: 9736 LAY SUMMARY Irritable bowel syndrome with constipation
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 2Q17 April May
BRAND NAME Trulance GENERIC NAME Plecanatide MANUFACTURER Synergy Pharmaceuticals, Inc. DATE OF APPROVAL January 19, 2017 PRODUCT LAUNCH DATE Anticipated in 1Q2017 REVIEW TYPE Review type 1 (RT1): New
More informationPharmacotherapy for IBS
Pharmacotherapy for IBS Brooks D. Cash, M.D., FACG Chief, Gastroenterology Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Disclosures I have served
More informationMANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES
Enrique Rey Professor of Medicine Head. Department of Digestive Diseases Hospital Clínico San Carlos Complutense University Madrid, Spain MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES CONSTIPATION:
More informationPRODUCT MONOGRAPH. Linaclotide capsules. 72 mcg, 145 mcg and 290 mcg linaclotide. Guanylate Cyclase-C Agonist
PRODUCT MONOGRAPH Pr CONSTELLA Linaclotide capsules 72 mcg, 145 mcg and 290 mcg linaclotide Guanylate Cyclase-C Agonist Allergan Inc. 85 Enterprise Blvd., Suite 500 Markham, Ontario L6G 0B5 Date of Preparation:
More informationOpioid-Induced Constipation
Objectives Opioid-Induced Constipation Brianna Jansma, PharmD Alex Smith, PharmD Megan Robinson, PharmD Summarize epidemiology of opioid-induced constipation (OIC) Understand opiates effects on the gastrointestinal
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationIrritable bowel syndrome (IBS) is a prevalent chronic
GASTROENTEROLOGY 2013;145:1334 1346 Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3 0,5 0 -Monophosphate JOEL CASTRO, 1,2
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationCurrent and Emerging Pharmacological Treatments in Irritable Bowel Syndrome
Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School What is the general
More informationLinaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity
1130-0108/2013/105/6/345-354 Revista Española de Enfermedades Digestivas Copyright 2013 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid Vol. 105, N.º 6, pp. 345-354, 2013 POINT OF VIEW Linaclotide in
More informationDrug Evaluation. Use of lubiprostone in constipating disorders and its potential for opioid-induced bowel dysfunction
Use of lubiprostone in constipating disorders and its potential for opioid-induced bowel dysfunction Lubiprostone is a novel medication, approved by the US FDA for the treatment of chronic idiopathic constipation
More informationAdvancing gastroenterology, improving patient care
American College of Gastroenterology Advancing gastroenterology, improving patient care Note to Visitors: A fully updated ACG Systematic Review on the Management of Chronic Idiopathic Constipation and
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationChronic constipation in the elderly
Chronic constipation in the elderly 1 Dec,2011 R 2 Natta Asanaleykha Epidemiology Definition Scope The impact of chronic constipation in the elderly Pathophysiology Evaluation the elderly patient with
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationWilliam D. Chey, MD Professor of Medicine University of Michigan
Evidence-based Treatment Strategies for IBS William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria for IBS Recurrent abdominal pain or discomfort at least 3 days / month in
More informationAPDW 2016 Poster No. a90312
APDW 2016 Poster No. a90312 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients with IBS-C Results of a multi-center,
More informationPrimary Management of Irritable Bowel Syndrome
Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)
More informationAntidiarrheals Antidiarrheal
Antidiarrheals Major factors in diarrhea Increased motility of the GI tract. Decreased absorption of fluid. Antidiarrheal drugs include: Antimotility agents. Adsorbents. Drugs that modify fluid and electrolyte
More information10/10/16. Disclosures. Educational Objectives
Nimish Vakil, MD, FACP, FACG, AGAF, FASGE Clinical Adjunct Professor University of Wisconsin Madison, Wisconsin Disclosures All faculty, course directors, planning committee, content reviewers and others
More informationAlimentary Pharmacology and Therapeutics SUMMARY
Alimentary Pharmacology and Therapeutics Randomised clinical trials: linaclotide phase 3 studies in IBS-C a prespecified further analysis based on European Medicines Agency-specified endpoints E. M. M.
More informationIrritable Bowel Syndrome: Current and Emerging Treatment Options
Irritable Bowel Syndrome: Current and Emerging Treatment Options Lauren Peyton, PharmD, CDE; and Joy Greene, PharmD INTRODUCTION Irritable bowel syndrome (IBS), one of the most prevalent functional gastrointestinal
More informationGuidelines NICE, not NICE and the Daily Mail. Dr Andy Poullis Consultant Gastroenterologist
Guidelines NICE, not NICE and the Daily Mail 2018 Dr Andy Poullis Consultant Gastroenterologist Coeliac IBS Gall bladder polyps PEI PPI Who to test for Coeliac persistent unexplained abdominal or gastrointestinal
More informationThe Role of Nonclinical Data in Assumptions of Extrapolation
The Role of Nonclinical Data in Assumptions of Extrapolation Tracy Behrsing, Ph.D. Pharmacologist FDA/CDER/OND/DGIEP (Disclaimer: Opinions expressed do not necessarily reflect those of the FDA or its policy)
More informationEfficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club
Efficacy and Safety of Lubiprostone Laura Wozniak February 23, 2010 K30 Monthly Journal Club Objectives Brief overview of constipation Review of article Discussion Constipation in Children 3-5% of all
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide
More informationElderly Man With Chronic Constipation
Elderly Man With Chronic Constipation Linda Nguyen, MD Director, Neurogastroenterology and Motility Clinical Assistant Professor Stanford University Overview Normal bowel function Defining Constipation:
More information... SELECTED ABSTRACTS...
... SELECTED ABSTRACTS... The following abstracts, from medical journals containing literature on irritable bowel syndrome, were selected for their relevance to this supplement. A Technical Review for
More informationWilliam D Chey, 1 Anthony J Lembo, 2 James A Phillips, 3 David P Rosenbaum 4
Efficacy and safety of tenapanor in patients with constipationpredominant irritable bowel syndrome: a 12-week, double-blind, placebocontrolled, randomized phase 2b trial William D Chey, 1 Anthony J Lembo,
More informationNicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia
More informationDisorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional
More informationTitle: Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome
Title: Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome Authors: Fernando Geijo Martínez, Ana Sánchez Garrido, Héctor Marcos Prieto, Concepción Piñeiro Pérez,
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More informationOriginal Research. for the treatment of CIC. Tegaserod was approved for the treatment
Original Research Economic Evaluation of Linaclotide for the Treatment of Adult Patients With Chronic Idiopathic Constipation in the United States Huan Huang, PhD; 1 Douglas C.A. Taylor, MBA; 2 Robyn T.
More informationIntestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response
Intestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response Blanca Serrano, 1 Silvia Delgado-Aros, 2 Fermín Mearin, 3 Constanza
More informationROME IV CRITERIA FOR IBS
PRACTICAL CONSIDERATIONS IN THE MANAGEMENT OF IBS BRENDA HORWITZ MD PROFESSOR OF CLINICAL MEDICINE LEWIS KATZ SCHOOL OF MEDICINE AND TEMPLE UNIVERSITY HEALTH SCIENCES CENTER OR THINGS I ALWAYS WANTED TO
More informationCurrent Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation
Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation Anthony Lembo, M.D. Associate Professor of Medicine Harvard Medical School Director, GI Motility Center Beth
More informationIBS - Definition. Chronic functional disorder of GI generally characterized by:
IBS - Definition Chronic functional disorder of GI generally characterized by: 3500 3000 No. of Publications 2500 2000 1500 1000 Irritable Bowel syndrome Irritable Bowel Syndrome 500 0 1968-1977 1978-1987
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. doi: /ajg.2017.
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo- Controlled Efficacy and Safety Trial The Harvard community has made this article
More informationConstipation: pathophysiology and management
REVIEW C URRENT OPINION Constipation: pathophysiology and management Arnold Wald Purpose of review Continuing advances in pharmaceutical development are providing an expanding array of treatment approaches
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationIrritable Bowel Syndrome and Chronic Constipation
Title slide - part 1 Irritable Bowel Syndrome and Chronic Constipation IBS - Physiologic Research Stress affects GI function Meals Pain / motility Time Line of Physiologic Research in IBS Pain sensitivit
More informationDo Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Do Probiotics Provide Adequate Relief
More informationBackground Velusetrag is an orally active 5-HT 4 receptor agonist of potential benefit in treating chronic idiopathic constipation.
Alimentary Pharmacology and Therapeutics Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT 4 agonist with high intrinsic activity, in chronic idiopathic constipation a 4-week,
More informationOPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES
OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES Introduction Introduction Mean faecal weight 128 g / cap / day Mean range 51-796 g Absolute range 15-1505 g Main factors affecting mass are caloric intake,
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Symproic GENERIC NAME Naldemedine MANUFACTURER Shionogi Inc. DATE OF APPROVAL March 23, 2017 PRODUCT LAUNCH DATE Anticipated to launch mid-summer 2017 REVIEW TYPE Review type 1 (RT1): New Drug
More informationLINZESS (linaclotide) capsules, for oral use Initial U.S. Approval: 2012
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LINZESS safely and effectively. See full prescribing information for LINZESS. LINZESS (linaclotide)
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
25 September 2014 EMA/CHMP/266108/2014 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on ' Guideline on the evaluation of medicinal products for the treatment of irritable
More informationdaily; available as 10- mg g PO
Overview of the PRN: The Pain and Palliative Care PRN of ACCP is an organization of pharmacy practitioners, clinical scientists, pharmacy educators, and others. Its mission is to advance pain and palliative
More informationNuove terapie per il trattamento della stipsi
Nuove terapie per il trattamento della stipsi Roberto De Giorgio DIMEC, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna 1088-2015 Un caso di gonfiore addominale F, 39 aa, BMI 18 -
More informationFUNCTIONAL GI DISORDERS ORIGINAL CONTRIBUTIONS
ORIGINAL CONTRIBUTIONS 763 see related editorial on page x Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and
More informationComparison of strategies and goals for treatment of chronic constipation among gastroenterologists and general practitioners
ORIGINAL ARTICLE Annals of Gastroenterology (18) 31, 1-6 Comparison of strategies and goals for treatment of chronic constipation among gastroenterologists and general practitioners Dan Carter a,c, Eytan
More informationJNM Journal of Neurogastroenterology and Motility
JNM Journal of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol. 20 No. 2 April, 2014 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm.2014.20.2.141 Review Emerging Pharmacologic
More informationAmitiza. Amitiza (lubiprostone) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.22 Subject: Amitiza Page: 1 of 5 Last Review Date: March 16, 2018 Amitiza Description Amitiza (lubiprostone)
More informationConstipation an Old Friend. Presented by Dr. Keith Harris
Constipation an Old Friend Presented by Dr. Keith Harris Irregularity and the Tricks of the Trade." CONSTIPATION What is constipation? INFREQUENT BOWEL MOVEMENTS DIFFICULTY DURING DEFECATION SENSATION
More informationChronic idiopathic constipation is defined by infrequent or difficult passage
NEW DRUG REVIEW Lubiprostone: A New Drug for the Treatment of Chronic Idiopathic Constipation Danial E. Baker, PharmD, FASCP, FASHP College of Pharmacy, Washington State University Spokane, Spokane, WA
More informationEvolving Therapy in Irritable Bowel Syndrome (IBS)
Evolving Therapy in Irritable Bowel Syndrome (IBS) Dr. Syed Mohammad Arif MBBS, FCPS (Medicine), MD (Gastro) Associate Professor Department of Medicine Dhaka Medical College A good set of bowels is worth
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationNew Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia
More informationCommon Gastrointestinal Problems in the Elderly
Common Gastrointestinal Problems in the Elderly Brian Viviano, D.O. Objectives Understand the pathophysiology, clinical manifestations, diagnosis and management of GI diseases of the elderly. Differentiate
More informationUnderstanding & Alleviating Constipation. Living (Well!) with Gastroparesis Program Warm-Up Class
Understanding & Alleviating Constipation Living (Well!) with Gastroparesis Program Warm-Up Class Please Remember The information presented is for educational purposes only and is in no way intended as
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationDiagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider
Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider Elizabeth Coss, MD General Gastroenterologist Audie Murphy Veterans Hospital UT Health This presentation does not
More informationChildhood constipation, a real problem..? Marc Benninga, Emma Children s Hospital, AMC, Amsterdam, the Netherlands
Childhood constipation, a real problem..? Marc Benninga, Emma Children s Hospital, AMC, Amsterdam, the Netherlands Constipation 0-10% >10-20% >20-30% >30-40% Mugie SM, et al. Best Pract & Res Clin Gastroenterol
More informationFOOT OFF THE BRAKES. Kerri Novak MD MSc FRCPC. Chronic Constipation: Taking the Foot off the Brakes Dr. Kerri Novak
CHRONIC CONSTIPATION: TAKING THE FOOT OFF THE BRAKES Kerri Novak MD MSc FRCPC www.seacourses.com 1 OUTLINE Epidemiology i Quality of life Approach Therapies www.seacourses.com 2 DEFINING CHRONIC CONSTIPATION
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationWhat Is Constipation?
CONSTIPATION What Is Constipation? Constipation is when you have infrequent or hard-to-pass bowel movements (meaning they are painful or you have to strain), have hard stools or feel like your bowel movements
More informationAlternating bowel pattern: what do people mean?
Alimentary Pharmacology & Therapeutics Alternating bowel pattern: what do people mean? R. S. CHOUNG*, G. R. LOCKE III*, A. R. ZINSMEISTER, L.J.MELTONIIIà &N.J.TALLEY* *Dyspepsia Center and Division of
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationRecent advances in pharmacological treatment of irritable bowel syndrome
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i27.8867 World J Gastroenterol 2014 July 21; 20(27): 8867-8885 ISSN 1007-9327 (print)
More informationWhat s the Latest? Rome III Criteria for IBS
Irritable Bowel lsyndrome: What s the Latest? American College of Gastroenterology Las Vegas, January 2014 Bi Brian E. Lacy, Ph.D., PhD M.D., MD FACG Professor of Medicine Geisel School of Medicine at
More informationFood Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence
Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence Maria Vazquez Roque, MD, MSc Assistant Professor Gastroenterology and Hepatology 2010 MFMER slide-1 Objectives Gluten-free
More informationIrritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center
Ti tl e s l i d e - p a rt 1 Irritable Bowel Syndrome and Chronic Constipation Susan Lucak, M.D. Columbia University Medical Center Treatment of IBS Abdominal pain / discomfort Antispasmodics Antidepressants
More informationPrevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria
ORIGINAL RESEARCH Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria Hiroto Miwa Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College
More informationSYMPROIC (naldemedine tosylate) oral capsule
SYMPROIC (naldemedine tosylate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationWhat location in the gastrointestinal (GI) tract has tight, or impermeable, junctions between the epithelial cells?
CASE 32 A 17-year-old boy presents to his primary care physician with complaints of diarrhea for the last 2 days. The patient states that he just returned to the United States after visiting relatives
More informationCallisto Pharmaceuticals Amex: KAL. Rodman & Renshaw Investor Conference November 7, 2007 Gary S. Jacob, Ph.D., CEO
Callisto Pharmaceuticals Amex: KAL Rodman & Renshaw Investor Conference November 7, 2007 Gary S. Jacob, Ph.D., CEO CALLISTO PHARMACEUTICALS, INC. Certain statements made in this presentation are forward-looking.
More informationActive ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate.
NAME OF THE MEDICINE KLYX Enema Active ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate Sorbitol C20H37NaO7S MW: 444.56 CAS no: 577-11-7
More informationProtectives and Adsorbents. Inorganic chemistry Course 1 Third year Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry
Protectives and Adsorbents Inorganic chemistry Course 1 Third year 2016-2017 Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry Protectives and Adsorbents This group of gastrointestinal agents
More information